Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.35) by 42.86 percent. This is a 66.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $159.882 million which beat the analyst consensus estimate of $149.535 million by 6.92 percent. This is a 43.26 percent increase over sales of $111.600 million the same period last year.